Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Onkure Therapeutics Inc OKUR

Healthcare Biotechnology
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors... see more

Current News (NDAQ:OKUR)

OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire 1 day ago

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

GlobeNewswire November 6, 2025

OnKure Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire November 4, 2025

OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

GlobeNewswire August 12, 2025

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

GlobeNewswire May 6, 2025

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

GlobeNewswire March 10, 2025

OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

GlobeNewswire March 4, 2025

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

GlobeNewswire December 10, 2024

OnKure Announces New Date for Upcoming Investor Call

GlobeNewswire November 25, 2024
View More News ››

Opinion & Analysis (NDAQ:OKUR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:OKUR)

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM): Suspending Mavode

http://beyondspx.com/2024/08/01/reneo-pharmaceuticals-inc-nasdaqrphm-suspending-mavodelpar-development-evaluating-strategic-alternatives/
MikeTester - August 1, 2024
View more Bullboard ››

AJA Health and Wellness Inc

AJA Health and Wellness Inc

AJA Health and Wellness Inc. operates a telemedicine platform and full-service travel clinics. The company offers virtual ...
View More »

Podcasts